We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Element Solutions (ESI) Up 31% YTD: What's Behind the Rally?
Read MoreHide Full Article
Element Solutions Inc.'s (ESI - Free Report) shares have shot up around 30.6% year to date, broadly outperforming the industry’s rise of 1.5%. The company has also topped the S&P 500’s 16% growth over the same period.
Image Source: Zacks Investment Research
Let’s discuss the factors behind this Zacks Rank #2 (Buy) stock’s price surge.
What’s Driving the Stock?
Impressive first-quarter results and bullish prospects have contributed to the company’s share price gain. It recorded adjusted earnings of 37 cents per share for the first quarter, beating the Zacks Consensus Estimate of 32 cents. It generated net sales of $550.1 million, up around 22% year over year.
The company announced an increase in its guidance for 2021. It raised its adjusted earnings guidance to at least $1.30 per share from the prior view of $1.10-$1.15 and expects adjusted EBITDA in the band of $500-$510 million. Moreover, the company anticipates generating free cash flow of $285 million in 2021, up from $275 million expected earlier.
Element Solutions’ high-end electronics business is witnessing robust demand. This apart, a spur in demand across the industrial economy in the first quarter acted as a tailwind.
Moreover, it stands to expand from strategic acquisitions. The recent acquisition of H.K. Wentworth is expected to augment growth in its electronics portfolio. The Kester acquisition has also supplemented business capabilities and scale to its existing electronics assembly materials unit. The DMP buyout brought about an expansion in Element Solutions’ technological investment to provide innovative solutions. The cash proceeds from the divestment of its Agricultural Solution Unit permit the company to invest in markets of strategic importance, and continue mergers and acquisitions.
Additionally, it is poised to gain from cost control, corporate reorganization, economical procurement and supply-chain initiatives in 2021.
Element Solutions remains committed to boost shareholders' returns. It generated $24 million of free cash flow in the first quarter of 2021. The company continues to look for opportunities to deploy excess capital.
Earnings estimates for Element Solutions have been increasing over the past three months. The Zacks Consensus Estimate for 2021 earnings has increased 15.1%. The consensus mark for 2022 earnings has also increased around 18% over the same time frame. The favorable estimate revisions instill investors’ confidence in the stock.
Cabot has a projected earnings growth rate of 125.9% for the current year. The company’s shares have surged 54.9% over a year.
Avient has a projected earnings growth rate of 64.1% for the current year. The company’s shares have jumped 82.6% over a year.
Ferro has a projected earnings growth rate of 54.3% for the current year. The company’s shares have increased 87.1% over a year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better. See these 7 breakthrough stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Element Solutions (ESI) Up 31% YTD: What's Behind the Rally?
Element Solutions Inc.'s (ESI - Free Report) shares have shot up around 30.6% year to date, broadly outperforming the industry’s rise of 1.5%. The company has also topped the S&P 500’s 16% growth over the same period.
Image Source: Zacks Investment Research
Let’s discuss the factors behind this Zacks Rank #2 (Buy) stock’s price surge.
What’s Driving the Stock?
Impressive first-quarter results and bullish prospects have contributed to the company’s share price gain. It recorded adjusted earnings of 37 cents per share for the first quarter, beating the Zacks Consensus Estimate of 32 cents. It generated net sales of $550.1 million, up around 22% year over year.
The company announced an increase in its guidance for 2021. It raised its adjusted earnings guidance to at least $1.30 per share from the prior view of $1.10-$1.15 and expects adjusted EBITDA in the band of $500-$510 million. Moreover, the company anticipates generating free cash flow of $285 million in 2021, up from $275 million expected earlier.
Element Solutions’ high-end electronics business is witnessing robust demand. This apart, a spur in demand across the industrial economy in the first quarter acted as a tailwind.
Moreover, it stands to expand from strategic acquisitions. The recent acquisition of H.K. Wentworth is expected to augment growth in its electronics portfolio. The Kester acquisition has also supplemented business capabilities and scale to its existing electronics assembly materials unit. The DMP buyout brought about an expansion in Element Solutions’ technological investment to provide innovative solutions. The cash proceeds from the divestment of its Agricultural Solution Unit permit the company to invest in markets of strategic importance, and continue mergers and acquisitions.
Additionally, it is poised to gain from cost control, corporate reorganization, economical procurement and supply-chain initiatives in 2021.
Element Solutions remains committed to boost shareholders' returns. It generated $24 million of free cash flow in the first quarter of 2021. The company continues to look for opportunities to deploy excess capital.
Earnings estimates for Element Solutions have been increasing over the past three months. The Zacks Consensus Estimate for 2021 earnings has increased 15.1%. The consensus mark for 2022 earnings has also increased around 18% over the same time frame. The favorable estimate revisions instill investors’ confidence in the stock.
Element Solutions Inc. Price and Consensus
Element Solutions Inc. price-consensus-chart | Element Solutions Inc. Quote
Other Stocks to Consider
Other top-ranked stocks in the basic materials space include Cabot Corporation (CBT - Free Report) , Avient Corporation (AVNT - Free Report) and Ferro Corporation , each holding a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cabot has a projected earnings growth rate of 125.9% for the current year. The company’s shares have surged 54.9% over a year.
Avient has a projected earnings growth rate of 64.1% for the current year. The company’s shares have jumped 82.6% over a year.
Ferro has a projected earnings growth rate of 54.3% for the current year. The company’s shares have increased 87.1% over a year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>